Tagged with BI

MEA The Middle East and Africa (MEA) medtech market is expected to grow from a value of USD 16.6 billion in 2019 to USD 21.8 billion at a CAGR of 3.6 percent by 2027, according to Business Market Insights. Read on for five crucial trends impacting MEA medtech and how the…

Saudi Arabia IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from procurement to regulatory, reimbursement, clinical trials, localisation, health economics, and digitalisation. Mostafa also outlines how IQVIA has adapted its Saudi…

Adl Biopharma ADL Biopharma is a Spanish CDMO and, according to its CEO, owner of Europe’s largest fermenter. Ignacio Urbelz, CEO, reveals how, after a tumultuous time that saw the company go bankrupt in 2013 and change ownership in 2020, the organization has reorganized with the intention of returning to its 1990s…

Kenya Medicines for Africa’s Lenias Hwenda examines the significance of Moderna’s USD 500 million investment into African manufacturing, other agreements in place to boost manufacturing capacity on the continent, and why a more equally distributed global pharmaceutical manufacturing network is in the interest of the entire planet.   Many Africans welcome…

Global The top COVID-19 Vaccines by revenue in 2021 and sales projections for 2022 based on Airfinity’s COVID-19 Vaccine Market Revenue Forecast 2022. Pfizer/BioNTech’s vaccine stands to make USD 42.69 billion in 2022, while Moderna’s product has projected sales of USD 25.71 billion. Projected USD 3.97 billion sales for Russia’s Sputnik…

UAE Fokion Sinis, Sanofi Vaccines’ General Manager for the Greater Gulf Multi Country Organisation, outlines some of the key impacts that the COVID-19 pandemic has had on the vaccine industry, the five ‘A’s of successful vaccination campaigns, and his ambitions for the future at a moment of great transformation for both…

Germany The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case for broader use of its diabetes drug.   Bayer’s 2021 annual report: €44.1 billion revenue, Crop Science grows double digits,…

China Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either from a domestic firm or one of the two international products (Pfizer/BioNTech and Moderna) currently approved elsewhere.   As the…

Spain AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to reevaluate public funding mechanisms at a national and European level, and provides an explanation for Spain’s leadership in clinical trials…

Korea Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP certification from the US FDA in 2007 and another one to launch an initial public offering; an ascent that, while…

Europe A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’ shuttering of its US R&D footprint.   BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029:…

Spain Kern Pharma’s chairman and Grupo Indukern CEO, Raúl Díaz-Varela, explains the new strategic direction of the Spanish generics player, how their partnership with Celltrion to commercialise biosimilars has evolved, and analyses the main developments shaping the country’s generics industry, including regulatory changes and pricing policies. In addition, he comments on…